YY-mAbs Therapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Co.'s approved drug DANYELZA® (naxitamab-gqgk) was approved by the FDA, in combination with granulocyte-macrophage Colony-Stimulating factor for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. Co.'s product candidate, 131I-omburtamab, is in development for pediatric central nervous system/leptomeningeal metastases from neuroblastoma - a rare and life-threatening pediatric cancer We show 21 historical shares outstanding datapoints in our coverage of YMAB's shares outstanding history.
Understanding the changing numbers of YMAB shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like YMAB versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching YMAB by allowing them to research YMAB shares outstanding history
as well as any other stock in our coverage universe. |
Free YMAB Email Alerts:
Video: Shares Outstanding Importance
